Na Cocer Peptides 
ukwezi gushize
INGINGO ZOSE N'AMAKURU Y’IBICURUZWA BITANZWE KURI URU RUBUGA BISANZWE KUBURANISHA AMAKURU N'INTEGO Z'UBUREZI.
Ibicuruzwa byatanzwe kururu rubuga bigenewe gusa mubushakashatsi bwa vitro. Mu bushakashatsi bwa vitro (Ikilatini: * mu kirahure *, bisobanura mu bikoresho by'ibirahure) bikorwa hanze y'umubiri w'umuntu. Ibicuruzwa ntabwo ari imiti, ntabwo byemewe n’ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA), kandi ntigomba gukoreshwa mu gukumira, kuvura, cyangwa gukiza indwara iyo ari yo yose y’ubuvuzi, indwara, cyangwa indwara. Birabujijwe rwose n'amategeko kwinjiza ibyo bicuruzwa mumubiri wabantu cyangwa inyamaswa muburyo ubwo aribwo bwose.
Incamake
GLP-2, imiti igezweho, yitabiriwe cyane mubijyanye no kuvura metabolism. Nibintu byambere byisi byisi ya agonist ya glucagon isa na peptide-1 (GLP-1) reseptor hamwe na glucose iterwa na insulineotropique polypeptide (GIP). Binyuze muburyo bwihariye bwibikorwa, yigana ingaruka zisanzwe za GLP-1 na GIP, itanga uburyo bushya bwo kurwanya glucose yamaraso.
Igishushanyo 1 Uburyo bwibikorwa bya GLP-2 mumubiri wumuntu.
Uburyo bwibikorwa
Kugena imisemburo ya insuline na glucagon: GLP-2 yongera imisemburo ya insuline kandi igabanya irekurwa rya glucagon muburyo buterwa na glucose. Iyo urugero rwa glucose rwamaraso ruzamutse, GLP-2 itera selile beta pancreatic beta gusohora insuline nyinshi, bityo kwihutisha gufata glucose no kuyikoresha no kugabanya urugero rwa glucose yamaraso; irabuza kandi gusohora glucagon, kugabanya umusaruro wa glucose ya hepatike, bikarushaho gukomera kurwego rwamaraso glucose. Ubu buryo bubiri bwo kugenzura bifasha kugumana umuvuduko wa glucose wamaraso, bikagabanya neza urugero glucose yisonzesha ndetse na nyuma yinyuma.
Guteza imbere guhaga no kugabanya ibiro: Uyu muti urashobora guteza imbere guhaga, bigatuma abarwayi bagabanya ibiryo bityo bagabanya ibiro. Kugabanya ibiro ni ingenzi ku barwayi bafite metabolisme yo mu bwoko bwa 2, kubera ko umubyibuho ukabije akenshi ufitanye isano rya bugufi no kurwanya insuline. Mugabanya ibiro, GLP-2 ifasha kunoza insuline, bigatuma umubiri urushaho kwitabira insuline bityo bikagenzura neza glucose yamaraso. Byongeye kandi, kugabanya ibiro bifasha kugabanya ibyago byingaruka nkindwara zifata umutima nimiyoboro yabarwayi ba metabolism.
Gutinda gusiba gastrica: GLP-2 itinda gusiba gastrica, kongera igihe ibiryo biguma mu gifu no gutinda kwinjira mu mara mato, bityo bikarinda umuvuduko mwinshi mubisukari byamaraso. Izi ngaruka zifasha guhagarika ihindagurika ryisukari yamaraso, cyane cyane mugucunga neza isukari yamaraso nyuma yinyuma, bigatuma habaho uburyo bwiza bwo kugenzura isukari mu maraso.
Kunoza ibimenyetso bya metabolike: Usibye ingaruka zabyo ku isukari yamaraso nuburemere, GLP-2 irerekana kandi ingaruka nziza mukuzamura urugero rwa lipide nibindi bimenyetso bya metabolike. Ubuvuzi bwa Clinical bwerekana ko bufasha kugabanya urugero rwa cholesterol ya lipoprotein (LDL) na triglyceride nkeya, bikazamura ubuzima bwa metabolike muri rusange kandi bikagabanya ibyago by’indwara zifata umutima n’umutima ku barwayi ba diyabete.
Gusaba
Mu bushakashatsi bwuzuye bwa SURPASS na SURMOUNT nini nini y’ubuvuzi bwa Phase III, GLP-2 yerekanye uburyo bwiza bwo kugenzura amaraso glucose. Ugereranije na placebo, GLP-2 yagabanije cyane urugero rwa hemoglobine A1c (HbA1c) mugihe nayo yerekana ingaruka nziza zo kugabanya ibiro. Imikorere yayo irenze iyyemewe na GLP-1 reseptor agonist. Mu bigeragezo bimwe na bimwe, abarwayi bavuwe na GLP-2 bagabanutse cyane mu rwego rwa HbA1c ndetse no kugabanya ibiro cyane, byerekana neza akamaro kayo no kuba byiza mu kurwanya glycemic no gucunga ibiro.
Kuvura Diyabete yo mu bwoko bwa 2: Nkumugereka wimirire nimyitozo ngororamubiri, GLP-2 itanga uburyo bwiza bwo kuvura abarwayi bafite metabolism yo mu bwoko bwa 2. Yaba ikoreshwa nka monotherapie cyangwa ifatanije nindi miti igabanya ubukana, GLP-2 itezimbere cyane glucose yamaraso.
Umwanzuro
Muri make, GLP-2 yerekana ibyiza mugucunga glucose yamaraso bitewe nuburyo bwihariye bwibikorwa nibikorwa byiza mugupima kwa muganga. Ntabwo igabanya gusa urugero rwa glucose yamaraso ahubwo inagira uruhare runini mugucunga ibiro no kunoza ibimenyetso bya metabolike.
Inkomoko
[1] Sood A, Kaur P, Syed O, n'abandi. Guhindura uburyo bwo kwita kuri metabolism: kwerekana ubushobozi bwa GLP-2 mugucunga glycemic no kurenga [J]. Impuguke zisubiramo Pharmacology Clinical, 2024,17 (3): 235-246.DOI: 10.1080 / 17512433.2024.2310070.
[2] Wong E, Cope R, Dima L, n'abandi. GLP-2: Indwara ya Glucose iterwa na Insulinotropic Polypeptide na Glucagon-isa na Peptide-1 Agonist yo gucunga indwara ya Diyabete yo mu bwoko bwa 2 [J]. Ikinyamakuru cyo muri Amerika cyo kuvura, 2023,30 (1): e26-e35.DOI: 10.1097 / MJT.000000000000151588.
[3] Kumar D, Harshidha D, Mousigan M, n'abandi. Incamake kuri GLP-2, Uburyo bubiri bwo kuvura Diyabete n'umubyibuho ukabije [J]. Ikinyamakuru mpuzamahanga cyubushakashatsi bushya & Gukura, 2022,7: 983.DOI: 10.5281 / zenodo.7420605.
[4] Chavda VP, Ajabiya J, Teli D, n'abandi. GLP-2, Igihe gishya cyo kuvura kabiri-Diyabete n'umubyibuho ukabije: Isubiramo rito [J]. Molekile, 2022.27 (13) .DOI: 10.3390 / molekile27134315.
[5] Forzano I, Varzideh F, Avvisato R, n'abandi. GLP-2: Amakuru agezweho [J]. Ikinyamakuru mpuzamahanga cya siyansi yubumenyi, 2022,23 (23) .DOI: 10.3390 / ijms232314631.
Ibicuruzwa biboneka mubushakashatsi bukoreshwa gusa:
